

CONFIDENTIAL

14 September 2012

[REDACTED]
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: [REDACTED]

Dear [REDACTED]

Patient Access Scheme proposal – axitinib – advanced renal cell carcinoma

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Pfizer for Inlyta (axitinib) for the treatment of advanced renal cell carcinoma. The proposal is for a simple discount scheme, with the discount applied to original invoices for purchases of axitinib for NHS patients.

I understand that Pfizer has proposed the simple discount PAS on the condition that the level of discount offered through the scheme should remain confidential and should not be published in final NICE guidance.

The Department is content for the PAS proposal to be considered in the relevant appraisal, with the level of discount remaining confidential.

NICE must, of course, be satisfied that sufficient information can be communicated to stakeholders to explain an appraisal recommendation. In this regard, what constitutes a sufficient level of transparency is a matter for the Institute to determine in developing its guidance. In addition, the NHS must have access to the discount price when final NICE guidance is made available, so Trusts and commissioners are able properly to account for the PAS.

Yours sincerely

[REDACTED]
Medicines, Pharmacy and Industry Group